Index

Note: Page numbers of article titles are in boldface type.

A

Accelerated hydrogen peroxide, for sterilization and high-level disinfection, 53
Active surveillance, in MDRO control, 187–189
Active surveillance cultures, in MRSA control, 164–170
Adenovirus, 237–238
AERs. See Automated endoscope reprocessors (AERs).
Alcohol-based hand rubs, 24–26
Alternative health care settings, infection prevention in, 271–283. See also specific settings and Infection prevention and control program(s).
Ambulatory care centers, infection prevention programs in, 278–281
  bioterrorism and disaster planning, 281
  communicable diseases and isolation management, 279
  environmental hygiene, 279–280
  safe injection practices, 280–281
Antibiotic(s). See also Antimicrobial.
Antibiotic-impregnated central venous catheters, in CLA-BSI prevention, 82–85
Anti-infective catheters, in CAUTI prevention, 111–112
Anti-infective “locks,” in CLA-BSI prevention, 86
Antimicrobial prophylaxis, perioperative, in surgical site infection prevention, 142–143
Antimicrobial stewardship, 245–260
  described, 245–246
  goals of, 246
  in MDRO control, 189–191
  in MRSA control, 171–172
  making business case for, 255
  strategies in, 249–254
    antibiotic cycling, 253–254
    clinical guidelines development and education approaches, 249–250
    computer-based decision support, 252–253
    postprescription review, 251–252
    preprescription approval, 250–251
Antimicrobial stewardship program
  essential participants in, 246–249
    clinical pharmacist, 247
    hospital administration, 247–248
    infection control and hospital epidemiology staff, 249
    infectious-disease physician, 246–247
    information technology, 247–248
    microbiology laboratory, 247–248
    Pharmacy and Therapeutics Committee, 248
  implementation and maintenance of, barriers to, 254–255
  measuring effect of, 255–257

doi:10.1016/S0891-5520(10)00110-8
0891-5520/11/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
Antiseptic-impregnated central venous catheters, in CLA-BSI prevention, 82–85
Antiseptic-impregnated sponge dressing placed at catheter exit site, in CLA-BSI prevention, 85–86
Aspergillosis
   in HSCT recipients, prevention of, 214
   prevention of, strategies for, 208–210
Aspergillus spp.
   nosocomial fungal infections due to, 205–206
   pneumonia due to, prevention of, 123–124
Automated endoscope reprocessors (AERs), for sterilization and high-level disinfection, 52–53
Avian influenza, 237

B
Bioterrorism and disaster planning, in ambulatory care centers, 281
Bloodstream infections, central line–associated, 77–102. See also Central line–associated bloodstream infections (CLA-BSIs).

C
Candida spp., nosocomial fungal infections due to, 202–204
Candidemia, catheter-related, intravascular, prevention of, 208
Candidiasis
   invasive, in HSCT recipients, prevention of, 212–214
   prevention of, strategies for, 208
Catheter(s)
   anti-infective, in CAUTI prevention, 111–112
   central venous, antibiotic- or antiseptic-impregnated, in CLA-BSI prevention, 82–85
   urinary. See Urinary catheters.
Catheter-associated urinary tract infections (CAUTIs), prevention of, 107–112
   alternatives to indwelling urinary catheters in, 110
   anti-infective catheters in, 111–112
   aseptic techniques for insertion and maintenance of urinary catheters in, 110–111
   early removal of urinary catheters in, 108–109
   general strategies in, 107–108
   limitation of use of urinary catheters in, 108–109
   perioperative management of urinary retention in, 109–110
   specific strategies in, 108
CAUTIs. See Catheter-associated urinary tract infections (CAUTIs).
CDC. See Centers for Disease Control and Prevention (CDC).
Centers for Disease Control and Prevention (CDC), in regulation and requirements of infection prevention and control, 1–2, 274
Central line–associated bloodstream infections (CLA-BSIs), 77–102
   diagnosis of, 87–92
   impact of CLA-BSIS on, 78–79
   incidence of, 78
   management of, 92–94
   pathogenesis of, 81
   pathogens associated with, 79–81
   prevalence of, 78
prevention of, 82–87
  antibiotic- or antiseptic-impregnated central venous catheters in, 82–85
  anti-infective “locks” in, 86
  antiseptic-impregnated sponge dressing placed at catheter exit site in, 85–86
  approaches not to be considered in, 86–87
  basic recommendations, 82
  chlorhexidine washes in, 85
  guidelines implementation in, 87
  risk factors for, 81
  surveillance of, 92
  terminology associated with, 77–78
Central venous catheters, antibiotic- or antiseptic-impregnated, in CLA-BSI prevention, 82–85
Chlorhexidine
  in CLA-BSI prevention, 85
  routine bathing with, in MRSA control, 171
CLA-BSIs. See Central line–associated bloodstream infections (CLA-BSIs).
Clinical pharmacist, in antimicrobial stewardship program, 247
Coagulation, infrared, reprocessing of, in sterilization and high-level disinfection, 62
Communicable diseases and isolation management, in ambulatory care centers, 279

D
Data programmer and analyst, in infection prevention and control program, 5–6
Decolonization, in MRSA control, 171
Disaster planning, in ambulatory care centers, 281
Disinfection
  high-level, 45–76
    described, 45–46
    new technologies for, 50–53
      accelerated hydrogen peroxide, 53
      AERs, 52–53
    reprocessing semicritical items in, 53–62
    rational approach to, 46–50

E
Endocavitary probes, reprocessing of, in sterilization and high-level disinfection, 58–59
Endoscope(s), reprocessing of, in sterilization and high-level disinfection, 53–57
Environmental cleaning, 62–65
  described, 45–46
  in MRSA control, 172
Environmental hygiene, in ambulatory care centers, 279–280
Epidemiology, in infection control, 265–268
  described, 265
  incidence of, 266–268
  prevalence of, 265–266

F
Federal Nursing Home Reform Act, from OBRA, 278
Fungal infections, nosocomial, 201–225. See also Nosocomial fungal infections. Fusarium spp., nosocomial fungal infections due to, 207
Glucose control, in surgical site infection prevention, 143–144

H1N1 pandemic, 236–237
Hand hygiene, 21–43
  adherence of, 27–30
  improving of, 30–31
  alcohol-based hand rubs, 24–26
  efficacy of, studies of, 26–37
  guidelines for, evolution of, 23–24
  health care–associated infections, 31–37
  impact on microbial contamination in, 26–27
  importance of, 21
  in MDRO control, 184–185
  in MRSA control, 161–164
  in SNFs, 273
Hand rubs, alcohol-based, 24–26
HAP. See Health care–acquired pneumonia (HAP).
Health care settings. See also specific components or diseases.
  HAP in, prevention of, 117–133
  Mycobacterium tuberculosis in, prevention of, 117–133
Health care–acquired legionella, prevention of, 123–124
Health care–acquired pneumonia (HAP), in health care settings, 117–123
  case definitions, 118–119
  described, 117
  epidemiology of, 118
  prevention of, 119–123
  risk factors for, 119
Health care–acquired viral respiratory diseases, 227–244. See also specific types, e.g.,
  Respiratory syncytial virus (RSV).
  adenovirus, 237–238
  pandemic influenza, 236–237
  parainfluenza, 238
  RSV, 227–229
  seasonal influenza, 229–236
Health care–associated infections, hand hygiene and, 31–37
Hematopoietic stem cell transplantation (HSCT) recipients, fungal infections in, prevention
  of, strategies for, 210–214
Hospital administration, in antimicrobial stewardship program, 247–248
Hospital physician epidemiologist, in infection prevention and control program, 5
HSCT recipients. See Hematopoietic stem cell transplantation (HSCT) recipients.
Hydrogen peroxide vapor low-temperature sterilization, 50
Hygiene
  environmental, in ambulatory care centers, 279–280
  hand, 21–43. See also Hand hygiene.

I
Infection(s). See also specific types.
  surgical site, 135–155. See also Surgical site infections.
Index

Infection control, informatics and epidemiology in, 261–270
Infection control and hospital epidemiology staff, in antimicrobial stewardship program, 249
Infection control program(s), for TB, components of, 125–128
Infection Prevention and Control Committee (IPCC), of infection prevention and control program, 4–5
Infection prevention and control program(s), 1–19
ambulatory care centers, 278–281
building of, 1–19
budget preparation in, 8
business plan for, 13–16
economics in, 13–16
IPCC in, 4–5
meetings related to, 7
members involved in, 5–13
  administrative assistant, 6
  data programmer and analyst, 5–6
  hospital physician epidemiologist, 5
  infection preventist, 7
  medical director of infection prevention, 5
mission of, 4
outbreak investigation related to, 12
quality improvement in, 12–13
regulation and requirements in
  CDC in, 1–2
  emergence and development of, 1–4
  surveillance during, 8–12
values associated with, 4
vision of, 4
in alternative health care settings, 271–283
in SNFs, 271–278. See also Skilled nursing facilities (SNFs), infection prevention programs in.

Infection preventist
in infection prevention and control program, 7
in SNFs, 277–278

Influenza
avian, 237
pandemic, 236–237
seasonal, 229–236. See also Seasonal influenza.

Informatics, for health care epidemiology, 261–265
background of, 261
data for investigations, 264–265
data management, 262–264
data sources, 262
electronic surveillance for, examples of, 263–264

Information technology, in antimicrobial stewardship program, 247–248
Information transfer during care transitions, in SNFs, 272–273
Infrared coagulation, reprocessing of, in sterilization and high-level disinfection, 62
IPCC. See Infection Prevention and Control Committee (IPCC).
Isolation precautions
in MDRO control, 185–187
in SNFs, 274–275
L
Laryngoscope(s), reprocessing of, in sterilization and high-level disinfection, 62
Legionella, health care–acquired, prevention of, 123–124
“Locks,” anti-infective, in CLA-BSI prevention, 86

M
Malassezia spp., nosocomial fungal infections due to, 204–205
MDROs. See Multidrug-resistant organisms (MDROs).
Methicillin-resistant Staphylococcus aureus (MRSA)
control of, 155–179
  active surveillance cultures in, 164–170
  antimicrobial stewardship in, 171–172
  approaches to, 161–172
  contact precautions and isolation in, 170–171
  controversies related to, 161–172
  decolonization in, 171
  environmental cleaning in, 172
  hand hygiene in, 161–164
  routine bathing with chlorhexidine in, 171
  described, 155
  epidemiology of, 156–157
  infection control practices for, 157–160
  outcomes of, 160–161
Microbiology laboratory, in antimicrobial stewardship program, 247–248
Mold(s), nosocomial fungal infections due to, 205–208
  Aspergillus spp., 205–206
  Fusarium spp., 207
  Pneumocystis jiroveci, 208
  prevention of, strategies for, 208–210
  zygomycetes, 207
MRSA. See Methicillin-resistant Staphylococcus aureus (MRSA).
Multidrug-resistant organisms (MDROs)
described, 181–182
in SNFs, 274
other than MRSA, control of, 181–200
  challenges related to, 191–193
  opportunities in, 191–193
strategies for
  active surveillance, 187–189
  antimicrobial stewardship, 189–191
  evidence of effectiveness of, 184–191
  hand hygiene, 184–185
  isolation precautions and personal protective equipment, 185–187
  rationale for use, 182–183
Mycobacterium tuberculosis, in health care settings, prevention of, 117–133

N
Nosocomial fungal infections, 201–225
  aspergillosis, prevention of, strategies for, 208–210
candidiasis, prevention of, strategies for, 208
in HSCT recipients, prevention of, strategies for, 210–214
molds and, 205–208
prevention of, strategies for, 208–210
yeasts and, 202–205

O
OBRA. See **Omnibus Budget Reconciliation Act (OBRA).**
Omnibus Budget Reconciliation Act (OBRA), Federal Nursing Home Reform Act from, 278
Oversight committee, in SNFs, 278
Ozone sterilization, 52

P
Pandemic influenza, 236–237
Parainfluenza, 238
Perioperative antimicrobial prophylaxis, in surgical site infection prevention, 142–143
Personal protective equipment, in MDRO control, 185–187
Pharmacy and Therapeutics Committee, in antimicrobial stewardship program, 248
**Pneumocystis** spp.
- **P. jiroveci,** nosocomial fungal infections due to, 208
- pneumonia due to, in HSCT recipients, prevention of, 214
Pneumonia(s)
- **Aspergillus,** prevention of, 123–124
- health care–acquired, in health care settings, **117–133.** See also **Health care–acquired pneumonia (HAP), in health care settings.**
- **Pneumocystis,** in HSCT recipients, prevention of, 214
Prostate biopsy probes, reprocessing of, in sterilization and high-level disinfection, 60–61

R
Rehabilitation services, in SNFs, 276
Reprocessing semicritical items, in sterilization and high-level disinfection, 53–62
- endocavitary probes, 58–59
- endoscopes, 53–57
- infrared coagulation, 62
- laryngoscopes, 62
- prostate biopsy probes, 60–61
- tonometers, 57–58
Respiratory syncytial virus (RSV), 227–229
- epidemiology of, 227–228
- prevention and control of, 228–229
- transmission of, 228
RSV. See **Respiratory syncytial virus (RSV).**

S
Safe injection practices, in ambulatory care centers, 280–281
Seasonal influenza, 229–236
- epidemiology of, 229–231
- prevention and control of, 234–236
- transmission of, 231–234
Skilled nursing facilities (SNFs), infection prevention programs in, 271–278
described, 271–272
functions, components and oversight of, 272–278
hand hygiene, 273
infection preventist, 277–278
information transfer during care transitions, 272–273
isolation precautions, 274–275
MDROs, 274
outbreak management, 276
oversight committee, 278
rehabilitation services, 276
resident and employee health program, 276–277
surveillance for infections and antimicrobial usage, 275

Skin, human, skin flora and, 21–23
Skin flora, human skin and, 21–23
SNFs. See Skilled nursing facilities (SNFs).

Staff members, in infection prevention and control program, 8

Staphylococcus aureus, methicillin-resistant. See Methicillin-resistant Staphylococcus aureus (MRSA).

Sterilization, 45–76
described, 45–46
new technologies for, 50–53
   accelerated hydrogen peroxide, 53
   AERs, 52–53
   hydrogen peroxide vapor low-temperature sterilization, 50
   ozone sterilization, 52
rational approach to, 46–50
reprocessing semicritical items in, 53–62. See also Reprocessing semicritical items, in sterilization and high-level disinfection.

Surgical site infections, 135–155
diagnosis of, 136–138
epidemiology of, 135
outcomes of, 135–136
pathogenesis of, 138–140
   burden of inoculation, 139
   endogenous contamination, 138–139
   exogenous contamination, 139
   pathogen virulence, 139–140
prevention of, 140–145
   avoid shaving in, 143
   feedback to surgeon in, 144–145
   glucose control in, 143–144
   perioperative antimicrobial prophylaxis in, 142–143
   surveillance in, 144–145
risk factors for, 140
treatment of, 146

TB. See Tuberculosis (TB).

Tonometer(s), reprocessing of, in sterilization and high-level disinfection, 57–58
Trichosporon spp., nosocomial fungal infections due to, 205
Tuberculosis (TB)
  described, 124–125
  in health care settings, transmission of, 125
  prevention of, 124–128
Tuberculosis (TB) infection control program, components of, 125–128
2009 influenza A (H1N1) pandemic, 236–237

U
Urinary catheters
  aseptic techniques for insertion and maintenance of, in CAUTI prevention, 110–111
  indwelling, alternatives to, in CAUTI prevention, 110
  limitation of use and early removal of, in CAUTI prevention, 108–109
Urinary retention, perioperative management of, in CAUTI prevention, 109–110
Urinary tract infections (UTIs), 103–115
  catheter-associated, prevention of, 107–112. See also Catheter-associated urinary tract infections (CAUTIs), prevention of.
  causes of, microbial, 104–105
  diagnosis of, 106–107
  epidemiology of, 104–106
  pathogenesis of, 103–104
  risk factors for, 105–106
  surveillance of, 106–107
UTIs. See Urinary tract infections (UTIs).

Y
Yeast(s), nosocomial fungal infections due to, 202–205

Z
Zygomycetes, nosocomial fungal infections due to, 207